Given the modulation of TMPRSS2 expression by AR in prostate cells18, several clinical trials have been initiated to assess the therapeutic efficacy of enzalutamide in COVID-19 patients (ClinicalTrials.gov identifiers; NCT04475601 and NCT04456049). This evidence concerns the gene TMPRSS2 and COVID-19.